Relevium Provides Bi-Weekly Update to Management Cease Trade Order
January 05 2022 - 1:13PM
Relevium Technologies Inc. (the “Company” or “Relevium”) (TSXV:
RLV) is providing an update to its previously disclosed management
cease trade order ("MCTO"), announced on November 1, 2021, in
respect of the audited annual financial statements and
corresponding management's discussion and analysis for the year
ended June 30, 2021, including the CEO and CFO certifications
(collectively, the “Annual Financial Filings”) that were not filed
by the required filing deadline of October 28, 2021 (the “Filing
Deadline”).
As previously disclosed, the Annual Financial
Filings were not filed on or before the Filing Deadline due to
audit resource scheduling and availability required to complete the
financial statements and disclosures.
The Company is working expeditiously on the
steps required to complete the Annual Financial Filings and expects
to be able to file the Annual Financial Filings by January 31,
2022. The Company will provide updates as further information
relating to the Annual Financial Filings becomes available.
The MCTO will be in effect until the Annual
Financial Filings are filed and requires that the Annual Financial
Filings be filed on or before January 31, 2022.
Until the Annual Financial Filings are filed,
the Company will issue bi-weekly default status reports in
accordance with National Policy 12-203 - Management Cease Trade
Orders. The Company intends to satisfy the provisions of the
Alternative Information Guidelines during the period it remains in
default of the filing requirements. The Company confirms that there
have been no material business developments or other material
information relating to its affairs as of the date of this news
release that have not been generally disclosed.
About Relevium Technologies
Inc.Relevium is a publicly traded Company that operates in
the health and wellness industry, including legal cannabis, with a
primary focus on online distribution. The principal business of the
Company is the identification, evaluation, acquisition and
operation of brands and businesses in the health and wellness
markets and medical cannabis. The Company pursues its business
strategy through an acquisition and partnership model in a holistic
approach to encompass a wide range of health and wellness consumer
products. Relevium operates through two wholly owned
subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition, and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including Walmart.com and
Amazon.com.
Biocannabix Health Corporation (BCX), based in
Montreal, Quebec, is a biopharma nutraceutical Company focused on
delivering pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
Cautionary Note Regarding Forward-Looking
Statements
This release includes certain statements and
information that may constitute forward-looking information within
the meaning of applicable Canadian and United States securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions, or expectations of future
performance, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", or "would" occur.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek to rely on the
applicable safe harbour.
On Behalf of the Board of DirectorsRELEVIUM TECHNOLOGIES
INC.Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.com Website:
www.releviumtechnologies.com Like us on FacebookFollow us on
TwitterFollow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Aug 2023 to Aug 2024